Drug intelligence / Profile preview

Ellagic acid

Development stage
Phase 4
Modality
Classical Binding Small Molecules → Small Molecules
Administration
Oral, Topical
01

Overview

Ellagic acid is a naturally occurring polyphenolic compound found in various fruits and vegetables such as pomegranates, strawberries, raspberries, cranberries, and walnuts. It is best known for its antioxidant and anti-proliferative properties. Ellagic acid has been studied as an investigational agent for several indications including follicular lymphoma (phase 2), protection from brain injury in intrauterine growth restricted babies (phase 1/2), improvement of cardiovascular function in obese adolescents (phase 2), and topical treatment of solar lentigines. Mechanistically, it acts by neutralizing free radicals to protect cells from oxidative stress; inhibiting chemical-induced carcinogenesis; down-regulating insulin-like growth factor II; activating tumor protein p53 / cyclin-dependent kinase inhibitor p21 expression leading to cell cycle arrest at the G1/S phase and apoptosis; inducing detoxification enzymes such as NADPH quinone reductase; inhibiting certain cytochrome P450 enzymes to prevent activation of procarcinogens; suppressing angiogenesis via vascular endothelial growth factor receptor type II signaling inhibition; blocking phosphatidylinositol‑4,5‑bisphosphate 3‑kinase (PI3K) / AKT pathway activity; stimulating apoptosis through transforming growth factor beta / Smad family member 3 signaling axis; inhibiting cyclin-dependent kinase 6 involved in cell cycle regulation; binding Alpha-actinin–4 to induce its degradation via the ubiquitin-proteasome pathway thereby reducing cancer cell motility and invasion[2][4][6][8]. Despite promising preclinical data on anticancer effects against multiple tumor types (e.g., breast cancer), clinical evidence remains limited due to poor absorption and rapid elimination from the body[1].

Other names
3,4,3',4'-hydroxyl-benzopyranol[5,4,3-c,d,e][1]benzopyrn-6-6'-dioneacide ellagiqueácido elágico
02

Targets

Cyp (Cyclophilin family)PDK (Pyruvate dehydrogenase kinase isoform 1)TP53 (Cellular Tumor Antigen p53 R175H)VEGFR2 (Vascular endothelial growth factor receptor 2)CDK6 (Cyclin-dependent kinase 6)IGF2 (Insulin-like growth factor 2)PI3K (Phosphoinositide-3-kinase regulatory subunit 6)

Beyond the preview

Go deeper on Ellagic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ellagic acid.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call